UB Paderborn / Katalog / Suche / in CDI

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The lancet oncology, 2017-01, Vol.18 (1), p.31-41

2017

Volltextzugriff (PDF)

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2980-2987

2016

Volltextzugriff (PDF)

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

The lancet oncology, 2011-08, Vol.12 (8), p.815-824

2011

Volltextzugriff (PDF)

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2018-04, Vol.36 (11), p.1143-1169

2018

Volltextzugriff (PDF)

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1061-1069

2013

Volltextzugriff (PDF)

Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers

Journal of clinical oncology, 2006-06, Vol.24 (17), p.2673-2678

2006

Volltextzugriff (PDF)

Towards evidence-based response criteria for cancer immunotherapy

Nature communications, 2023-05, Vol.14 (1), p.3001-3001, Article 3001

2023

Volltextzugriff (PDF)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Nature communications, 2022-06, Vol.13 (1), p.3607-3607, Article 3607

2022

Volltextzugriff (PDF)

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Journal of clinical oncology, 2010-01, Vol.28 (1), p.49-55

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

Journal of clinical oncology, 2006-08, Vol.24 (22), p.3693-3704

2006

Volltextzugriff (PDF)

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-01, Vol.27 (3), p.404-410

2009

Volltextzugriff (PDF)

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2253-2260

2009

Volltextzugriff (PDF)

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Cancer treatment reviews, 2017-03, Vol.54, p.43-57

2017

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1871-1878

2008

Volltextzugriff (PDF)

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211126-17588359221112696

2022

Volltextzugriff (PDF)

The impact of baseline Edmonton Symptom Assessment Scale scores on treatment and survival in patients with advanced non-small cell lung cancer

Clinical lung cancer, 2018-01, Vol.19 (1), p.e91-e99

2018

Volltextzugriff (PDF)

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2969-2979

2016

Volltextzugriff (PDF)

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

Journal of thoracic oncology, 2011-11, Vol.6 (11), p.1950-1954

2011

Volltextzugriff (PDF)

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

Clinical and translational science, 2021-03, Vol.14 (2), p.664-670

2021

Volltextzugriff (PDF)

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1363-1372

2018

Volltextzugriff (PDF)

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Volltextzugriff (PDF)

Targeted therapy in BRAF -mutated lung adenocarcinoma

The lancet oncology, 2016-05, Vol.17 (5), p.550-551

Laurie, Scott A

2016

Volltextzugriff (PDF)

A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization

Clinical cancer research, 2006-04, Vol.12 (8), p.2555-2562

2006

Volltextzugriff (PDF)

Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment

Thoracic surgery clinics, 2021-11, Vol.31 (4), p.399-406

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers

Towards evidence-based response criteria for cancer immunotherapy

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

The impact of baseline Edmonton Symptom Assessment Scale scores on treatment and survival in patients with advanced non-small cell lung cancer

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy in BRAF -mutated lung adenocarcinoma

A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization

Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment

Suchergebnisse filtern